20:08 , Oct 24, 2018 |  BC Innovations  |  Translation in Brief

Common drivers in neuroendocrine tumors

A University of California Los Angeles team is taking steps towards identifying new targets that could be exploited to address treatment-resistant small cell neuroendocrine tumors, regardless of tissue of origin. In a...
16:15 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; breast cancer; ovarian cancer Cell culture and mouse studies suggest niclosamide could help treat p53-mutant colorectal, ovarian and breast cancers. High throughput screening of a library of 1,600 approved compounds in p53-wild...
17:39 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies identified a Wnt/β-catenin pathway inhibitor and p53 activator that could help treat colorectal cancer. Screening of a small molecule library in a human cell-based assay of Wnt/β-catenin-dependent...
01:21 , Sep 21, 2018 |  BC Innovations  |  Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
23:37 , Sep 17, 2018 |  BC Extra  |  Tools & Techniques

AI code could speed cancer diagnosis, treatment decisions

New York University School of Medicine researchers described in...
22:49 , Aug 10, 2018 |  BC Extra  |  Preclinical News

New approach could identify Ras-blocking small molecules

With an eye on historically undruggable cancer target Ras, a University of Oxford team and colleagues devised a way to find small molecules that have the same qualities as Ras inhibitors too large to access...
00:38 , Aug 9, 2018 |  BC Innovations  |  Translation in Brief

Identifying the ubiquitinators

A team at University of Dundee and Newcastle University has developed a mass spectrometry-based screening platform to identify ubiquitin ligases and compounds that modulate them. The approach uses the uptake of ubiquitin by enzymes rather...
23:50 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC)...
20:12 , Aug 1, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cell-free assays; high throughput screening A high throughput, mass spectrometry-based screening assay could identify E3 ligase inhibitors and interactive pairs of E2/E3 ubiquitination enzymes as potential drug targets. For the latter, the method involves...
15:30 , Jul 25, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Zebrafish expressing human PAX3 and FOXO1 could be used to screen therapies for rhabdomyosarcoma. Zebrafish harboring M214K-mutant p53, engineered to express human PAX3 and FOXO1 and injected with a ubiquitous promoter...